139 related articles for article (PubMed ID: 27176780)
1. Targeted inhibition of dominant PI3-kinase catalytic isoforms increase expression of stem cell genes in glioblastoma cancer stem cell models.
Jones NM; Rowe MR; Shepherd PR; McConnell MJ
Int J Oncol; 2016 Jul; 49(1):207-16. PubMed ID: 27176780
[TBL] [Abstract][Full Text] [Related]
2. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
[TBL] [Abstract][Full Text] [Related]
4. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
5. Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition.
Iqbal A; Eckerdt F; Bell J; Nakano I; Giles FJ; Cheng SY; Lulla RR; Goldman S; Platanias LC
Oncotarget; 2016 May; 7(22):33192-201. PubMed ID: 27120806
[TBL] [Abstract][Full Text] [Related]
6. Defining the role of mTOR pathway in the regulation of stem cells of glioblastoma.
Jhanwar-Uniyal M; Gellerson O; Bree J; Das M; Kleinman G; Gandhi CD
Adv Biol Regul; 2023 May; 88():100946. PubMed ID: 36658088
[TBL] [Abstract][Full Text] [Related]
7. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.
Sunayama J; Matsuda K; Sato A; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Stem Cells; 2010 Nov; 28(11):1930-9. PubMed ID: 20857497
[TBL] [Abstract][Full Text] [Related]
8. Nitidine chloride inhibits the malignant behavior of human glioblastoma cells by targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Wang J; Qi Q; Huang B; Chen A; Li X; Wang J
Oncol Rep; 2016 Oct; 36(4):2160-8. PubMed ID: 27498786
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PLK4 might enhance the anti-tumour effect of bortezomib on glioblastoma via PTEN/PI3K/AKT/mTOR signalling pathway.
Wang J; Ren D; Sun Y; Xu C; Wang C; Cheng R; Wang L; Jia G; Ren J; Ma J; Tu Y; Ji H
J Cell Mol Med; 2020 Apr; 24(7):3931-3947. PubMed ID: 32126150
[TBL] [Abstract][Full Text] [Related]
10. Mammalian target of rapamycin inhibitors, temsirolimus and torin 1, attenuate stemness-associated properties and expression of mesenchymal markers promoted by phorbol-myristate-acetate and oncostatin-M in glioblastoma cells.
Chandrika G; Natesh K; Ranade D; Chugh A; Shastry P
Tumour Biol; 2017 Mar; 39(3):1010428317695921. PubMed ID: 28351321
[TBL] [Abstract][Full Text] [Related]
11. A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Ströbele S; Schneider M; Schneele L; Siegelin MD; Nonnenmacher L; Zhou S; Karpel-Massler G; Westhoff MA; Halatsch ME; Debatin KM
PLoS One; 2015; 10(6):e0131670. PubMed ID: 26121251
[TBL] [Abstract][Full Text] [Related]
12. PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition.
Zhao HF; Wang J; Jiang HR; Chen ZP; To SS
J Exp Clin Cancer Res; 2016 May; 35():78. PubMed ID: 27176481
[TBL] [Abstract][Full Text] [Related]
13. Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
Kim MJ; Koo JE; Han GY; Kim B; Lee YS; Ahn C; Kim CW
J Korean Med Sci; 2016 Mar; 31(3):360-70. PubMed ID: 26955235
[TBL] [Abstract][Full Text] [Related]
14. Role of mTOR in glioblastoma.
Duzgun Z; Eroglu Z; Biray Avci C
Gene; 2016 Jan; 575(2 Pt 1):187-90. PubMed ID: 26341051
[TBL] [Abstract][Full Text] [Related]
15. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
16. FoxO proteins or loss of functional p53 maintain stemness of glioblastoma stem cells and survival after ionizing radiation plus PI3K/mTOR inhibition.
Firat E; Niedermann G
Oncotarget; 2016 Aug; 7(34):54883-54896. PubMed ID: 27448972
[TBL] [Abstract][Full Text] [Related]
17. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
18. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
19. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.
Kolev VN; Wright QG; Vidal CM; Ring JE; Shapiro IM; Ricono J; Weaver DT; Padval MV; Pachter JA; Xu Q
Cancer Res; 2015 Jan; 75(2):446-55. PubMed ID: 25432176
[TBL] [Abstract][Full Text] [Related]
20. PIK3CB/p110β is a selective survival factor for glioblastoma.
Pridham KJ; Le L; Guo S; Varghese RT; Algino S; Liang Y; Fajardin R; Rodgers CM; Simonds GR; Kelly DF; Sheng Z
Neuro Oncol; 2018 Mar; 20(4):494-505. PubMed ID: 29016844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
